SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

PlasmaTech Biopharmaceuticals Inc. (PTBI)

Add PTBI Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator beambe, [SMART MONEY] , PennyMoocher69
Search This Board:
Last Post: 5/25/2015 1:46:28 PM - Followers: 92 - Board type: Free - Posts Today: 1


 Company Overview

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that focuses on adding value to exciting product concepts in research by advancing those products through clinical development. Access has adopted a semi-virtual model to control costs, and advances projects by utilizing its experienced clinical and regulatory team and a small team of experienced pharmaceutical scientists. Access's scientists have unique expertise in nanopolymer chemistry platform technologies, which are utilized in several of the company's R&D programs. Through careful strategic planning designed to maximize shareholder returns, Access will either seek to advance products towards regulatory and marketing approval, co-develop products in collaboration with R&D and marketing partners or out-license products once development has advanced to a predetermined point.

While the the company's primary focus is in oncology and supportive care of cancer patients, Access has recently acquired product candidates in the dermatology field as well as additional oncology assets. Access has an approved supportive care product, one product in Phase 3 clinical development, four Phase 2 clinical candidates, and six preclinical programs in oncology, including products arising from a promising oral drug delivery technology.

In the area of supportive care, Access has received marketing allowance for MuGard in the United States from the Food and Drug Administration (FDA). MuGard is indicated for management of mucositis. Mucositis is a debilitating side effect of various cancer treatments resulting in ulceration of the oral cavity. MuGard, a proprietary nanopolymer rinse formulation, provides a protective coating to the mucosal surfaces in the mouth. A clinical study has shown MuGard to be effective in lowering the incidence and severity of mucositis. The market for mucositis treatment is estimated to be in excess of US$1 billion world-wide. In addition to receiving FDA marketing allowance in the U.S., Access has marketing partners for MuGard in three major world territories; SpePharm, for the commercialization of MuGard in the EU, Milestone Biosciences for North America, and RHEI Pharmaceuticals for certain Asian territories

ProLindac links Access' nanopolymer technolgy with the principals of prodrugs to enhance the delivery of a platinum drug to tumors. In preclinical models ProLindac protects normal tissue from the cytotoxic drug while in circulation and enhances uptake of drugs to tumors, where drug is released by virtue of a pH-sensitive linker. ProLindac completed a Phase 1 clinical study demonstrating promising signs of efficacy. ProLindac has completed a Phase 2 clinical study in patients with recurrent ovarian cancer. The drug used in ProLindac is DACH platinum, which is also the active moiety of oxaliplatin (Eloxatin; Sanofi  Aventis), a drug which currently has sales of over $2.0 billion worldwide. Access has a codevelopment agreement with Nanjing Aosaikang Medicinal Group for development of ProLindac in China.

Thiarabine is a novel nucleoside product which demonstrated very promising anticancer activity in preclinical models. Following completion of two Phase 1 clinical studies, Access plans to advance thiarabine in a Phase 2 study at a leading US institute for the treatment of leukemia.

Access also has Cobalamin technologies in early-stage development. This technology is based upon the use of cobalamin coated particles derived from the company's nanopolymer chemistry technlogies. The company has extensive intellectual property surrounding the use of this technology for oral drug delivery including oral delivery of insulin and other proteins and peptides. Access receives funding from a major pharmaceutical company for the development of a Cobalamin oral drug delivery formulation of human growth hormone. In preclinical development are the Angiolix®, Prodrax®, Alchemix®, and Cobalamin programs, which have the potential to provide an exciting array of new clinical candidates.

Angiolix (HuMc3) is a humanized monoclonal antibody which binds to Lactadherin, a 46kDa extracellular matrix protein, expressed by most breast tumor cells. This binding blocks vascular endothelial cell proliferation, and induces selective programmed cell death (apoptosis) in blood vessels supporting tumors. This cuts off or reduces the supply of nutrients and oxygen to tumors and reduces tumor growth. Angiolix thus acts as an anti-angiogenesis factor like drugs such as Avastin. In preclinical studies, Angiolix displays potent anti-tumor activity in the MX-1 breast cancer tumor model.

Prodrax is a non-toxic prodrug which is targeted to be active in the low oxygen (hypoxic) regions of solid tumors. The Prodrax program comprises a series of compounds which are N-oxide prodrugs of cytotoxic anthraquinone derivatives. The N-oxide deactivates the toxic cytotoxic alkylating function while the drug is in circulation; it also serves to enhance the ability of the compound to traverse biological membranes, ensuring that the prodrug is widely distributed in the body. Prodrax compounds are non-toxic in normally oxygenated tissues as well as the oxygenated areas of solid tumors but become highly toxic in the low oxygen (hypoxic) region of tumors.

Alchemix molecules are proprietary molecules that attack tumors by two modes of action: through intercalating and alkylating properties that result in irreversible binding of the compounds to tumor DNA, thus preventing tumor replication and inducing tumor cell death. It has also been shown that Alchemix molecules are a potent inhibitors of topoisomerase II. Alchemix molecules possess potent activity across a variety of different human tumor cell lines and significantly show potent activity in cisplatin and anthracyline resistant xenograft human tumor models.

The Cobalamin oral drug delivery technology has been extended to provide nanoparticulate formulations for the enhanced targeting of drugs to sites of disease. Targeting results from the increased demand for vitamins such as cobalamin that often occurs at disease sites, such as cancer.

Access is developing Phenylbutyrate (PB) which is also in Phase 2 clinical trials. PB is a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. HDAC inhibitors have potent anticancer activity by suppressing specific enzymes found in cancer cells.

Access recently acquired two dermatological products as well as the proprietary nanopolymer drug delivery technology used in one of these products. Pexiganan is topical product for the treatment of diabetic foot ulcers. It is based on the proprietary synthetic analog of a naturally-occuring broad-spectrum antimicrobial peptide. Clinical studies have shown Pexiganan to be at least as effective as one of the standard oral antibiotics used in the treatment of diabetic foot ulcers, without the potential issues of systemic use of antibiotic. EcoNail is a nail lacquer for the treatment of onychomycosis, a common nail fungal infection.

Access Pharmaceuticals Inc.
2600 Stemmons Freeway
Suite 176
Dallas, TX 75207
United States - Map
Phone: 214-905-5100
Fax: 214-905-5101
Web Site:

Product Pipeline


Shares Outstanding5: 13.11M
Float: 8.82M
% Held by Insiders1: 35.59%
% Held by Institutions1: 1.30%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for PTBI
PTBI News: Amended Statement of Beneficial Ownership (sc 13d/a) 05/22/2015 04:02:57 PM
PTBI News: Small Company Offering and Sale of Securities Without Registration (d) 05/22/2015 03:05:46 PM
PTBI News: Current Report Filing (8-k) 05/18/2015 04:32:40 PM
PTBI News: Securities Registration Statement (simplified Form) (s-3) 05/15/2015 06:04:45 AM
PTBI News: Quarterly Report (10-q) 05/14/2015 04:26:50 PM
#1069   Jya just have to love all this cash tpizzazz24 05/25/15 01:46:28 PM
#1068   Probably why they kept the price under $9 theycallmejg15 05/23/15 09:52:29 AM
#1067   Looks like they had a small $10,000,000 offering shotcallers 05/22/15 07:05:30 PM
#1066   Yeah I was thinking about that theycallmejg15 05/21/15 11:08:40 AM
#1064   Looks like it bounced! theycallmejg15 05/21/15 09:57:04 AM
#1063   I'm still waiting on my apology. Stock performing KingDMC 05/20/15 06:41:00 PM
#1062   It's coming back theycallmejg15 05/20/15 03:04:24 PM
#1061   Well I agree with you on the heavy KingDMC 05/20/15 02:26:47 PM
#1059   ? KingDMC 05/20/15 12:23:07 PM
#1058   Im back in guys Shotor 05/20/15 12:20:27 PM
#1057   Did you buy @ $3? stockdawg44 05/20/15 10:49:07 AM
#1056   shorts love ya..... stockdawg44 05/20/15 10:48:17 AM
#1055   Traders blog has post, that there is scappy 05/20/15 10:44:16 AM
#1054   Correct, just orphan drug status approved. Prior barnstormer 05/20/15 10:32:50 AM
#1053   Next leg up to over $10.85 could spike stockstalk09 05/20/15 10:17:17 AM
#1052   News is on DJNW , has not hit crudeoil24 05/20/15 10:08:55 AM
#1051   Right on KingDMC 05/20/15 09:58:44 AM
#1050   Can we see 11 do I hear 11 Kcricket 05/20/15 09:58:00 AM
#1049   Dip and RIP!!!!!!! PTBI sweetness!!!! stockdawg44 05/20/15 09:56:59 AM
#1048   Looking good here! crudeoil24 05/20/15 09:55:46 AM
#1047   News has not hit IHUUB, MARKETWIRE, ETC. crudeoil24 05/20/15 09:43:58 AM
#1046   Looking for a lite bottom here then back Kcricket 05/20/15 09:37:56 AM
#1045   I think they only received orphan drug status KingDMC 05/20/15 09:26:10 AM
#1044   New news out! FDA approves their orphan drug! theycallmejg15 05/20/15 09:15:40 AM
#1043   I'll take it any day lol theycallmejg15 05/20/15 09:09:43 AM
#1042   George Soros stake holder here.... Dallas rocking....Dallas boys crudeoil24 05/20/15 08:51:49 AM
#1041   Exactly. Market giveth, we Tradeth. KingDMC 05/20/15 08:50:34 AM
#1040   At 9:30am after the open the pros will stockstalk09 05/20/15 08:43:15 AM
#1039   Like is said yesterday before the close, the stockstalk09 05/20/15 08:35:56 AM
#1038   NEWS >>> PlasmaTech Biopharma Gets FDA Designations for crudeoil24 05/20/15 08:28:18 AM
#1037   Already up to 10.40 pre-market. This stock is PennyMoocher69 05/20/15 08:22:29 AM
#1036   It settled below my avg. if I would've theycallmejg15 05/19/15 10:17:04 PM
#1035   Until the next momentum play takes over. Use KingDMC 05/19/15 10:15:30 PM
#1034   Can it sustain this huge jump then in curious 05/19/15 08:48:29 PM
#1033   Of course not. We'd be spending our money eatdogmeat 05/19/15 08:14:21 PM
#1032   If George Soros didn't invest in this stock curious 05/19/15 07:57:10 PM
#1031   The 12mil jumps drug down my the 1mil eatdogmeat 05/19/15 06:56:38 PM
#1030   OSP thanks bud $PTBI has been an ATM TheTradingNinja 05/19/15 06:51:48 PM
#1029   I just wonder how long this stock is theycallmejg15 05/19/15 06:18:22 PM
#1028   great call - another winner by the ninja! - ospreyeye 05/19/15 05:33:52 PM
#1027   Too smart not to flip... KingDMC 05/19/15 05:01:27 PM
#1026   Go on stocktwits. That's all they are talking theycallmejg15 05/19/15 04:59:36 PM
#1025   Oh no i understand your situation, but this KingDMC 05/19/15 04:58:37 PM
#1024   I would if I could. Someday I'll be theycallmejg15 05/19/15 04:50:02 PM
#1023   Smart traders.... KingDMC 05/19/15 04:06:29 PM
#1022   Numb nut sellers the last hour, too blind stockstalk09 05/19/15 04:03:51 PM
#1021   My sentiments exactly. Traders stock and should be KingDMC 05/19/15 04:03:36 PM
#1020   B-back plz Mike6565 05/19/15 03:16:03 PM
#1019   $PTBI - Up Nicely today - May 18, ospreyeye 05/19/15 01:59:58 PM
#1018   Cute... KingDMC 05/19/15 01:31:46 PM